These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
313 related articles for article (PubMed ID: 22115124)
1. Treatment of colorectal liver metastases. Ismaili N World J Surg Oncol; 2011 Nov; 9():154. PubMed ID: 22115124 [TBL] [Abstract][Full Text] [Related]
2. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Mauer M; Tanis E; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ; Lancet Oncol; 2013 Nov; 14(12):1208-15. PubMed ID: 24120480 [TBL] [Abstract][Full Text] [Related]
3. FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial. Hebbar M; Chibaudel B; André T; Mineur L; Smith D; Louvet C; Dutel JL; Ychou M; Legoux JL; Mabro M; Faroux R; Auby D; Brusquant D; Khalil A; Truant S; Hadengue A; Dalban C; Gayet B; Paye F; Pruvot FR; Bonnetain F; Landi B; Flesch M; Carola E; Martin P; Vaillant E; de Gramont A; Ann Oncol; 2015 Feb; 26(2):340-7. PubMed ID: 25403578 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer. Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098 [TBL] [Abstract][Full Text] [Related]
5. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727 [TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391 [TBL] [Abstract][Full Text] [Related]
7. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Carrato A; Abad A; Massuti B; Grávalos C; Escudero P; Longo-Muñoz F; Manzano JL; Gómez A; Safont MJ; Gallego J; García-Paredes B; Pericay C; Dueñas R; Rivera F; Losa F; Valladares-Ayerbes M; González E; Aranda E; Eur J Cancer; 2017 Aug; 81():191-202. PubMed ID: 28633089 [TBL] [Abstract][Full Text] [Related]
8. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases. Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681 [TBL] [Abstract][Full Text] [Related]
9. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919 [TBL] [Abstract][Full Text] [Related]
10. Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol. Boilève A; Maillard A; Wagner M; Dromain C; Laurent C; Dupont Bierre E; Le Sourd S; Audemar F; Ulusakarya A; Guerin-Meyer V; Smisth D; Pezzella V; De Baere T; Goere D; Gelli M; Taieb J; Boige V BMC Cancer; 2020 Jan; 20(1):74. PubMed ID: 32000724 [TBL] [Abstract][Full Text] [Related]
11. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585 [TBL] [Abstract][Full Text] [Related]
12. First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. Bond MJG; Bolhuis K; Loosveld OJL; de Groot JWB; Droogendijk H; Helgason HH; Hendriks MP; Klaase JM; Kazemier G; Liem MSL; Rijken AM; Verhoef C; de Wilt JHW; de Jong KP; Gerhards MF; van Amerongen MJ; Engelbrecht MRW; van Lienden KP; Molenaar IQ; de Valk B; Haberkorn BCM; Kerver ED; Erdkamp F; van Alphen RJ; Mathijssen-van Stein D; Komurcu A; Lopez-Yurda M; Swijnenburg RJ; Punt CJA; Lancet Oncol; 2023 Jul; 24(7):757-771. PubMed ID: 37329889 [TBL] [Abstract][Full Text] [Related]
13. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. Snoeren N; Voest EE; Bergman AM; Dalesio O; Verheul HM; Tollenaar RA; van der Sijp JR; Schouten SB; Rinkes IH; van Hillegersberg R BMC Cancer; 2010 Oct; 10():545. PubMed ID: 20937118 [TBL] [Abstract][Full Text] [Related]
14. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Bridgewater JA; Pugh SA; Maishman T; Eminton Z; Mellor J; Whitehead A; Stanton L; Radford M; Corkhill A; Griffiths GO; Falk S; Valle JW; O'Reilly D; Siriwardena AK; Hornbuckle J; Rees M; Iveson TJ; Hickish T; Garden OJ; Cunningham D; Maughan TS; Primrose JN; Lancet Oncol; 2020 Mar; 21(3):398-411. PubMed ID: 32014119 [TBL] [Abstract][Full Text] [Related]
15. Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973). Goéré D; Pignon JP; Gelli M; Elias D; Benhaim L; Deschamps F; Caramella C; Boige V; Ducreux M; de Baere T; Malka D BMC Cancer; 2018 Aug; 18(1):787. PubMed ID: 30081865 [TBL] [Abstract][Full Text] [Related]
17. Treatment for colorectal liver metastases: a review. Shimada H; Tanaka K; Endou I; Ichikawa Y Langenbecks Arch Surg; 2009 Nov; 394(6):973-83. PubMed ID: 19582473 [TBL] [Abstract][Full Text] [Related]
18. Treatment of colorectal liver metastases: a review. Van den Eynde M; Hendlisz A Rev Recent Clin Trials; 2009 Jan; 4(1):56-62. PubMed ID: 19149763 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Adam R Ann Oncol; 2003; 14 Suppl 2():ii13-6. PubMed ID: 12810452 [TBL] [Abstract][Full Text] [Related]
20. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Boige V; Malka D; Elias D; Castaing M; De Baere T; Goere D; Dromain C; Pocard M; Ducreux M Ann Surg Oncol; 2008 Jan; 15(1):219-26. PubMed ID: 17896145 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]